Learn More
Abcam CCG 1423, Rho pathway-mediated signaling inhibitor, 5MG
Supplier: Abcam AB2291815MG
MW 454.7 Da, Purity >98%. Specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. Displays activity in several in vitro cancer cell functional assays. Potently (<1 mumol/L) inhibits lysophosphatidic acid-induced DNA synthesis in PC-3 prostate cancer cells, inhibits growth of RhoC-overexpressing melanoma lines at nanomolar concentrations. Selectively stimulates apoptosis of the metastasis-prone, RhoC-overexpressing melanoma cell lines. Acts at or downstream of MLK1 and upstream of SRF. Blocks MLK1 nuclear localization.
The product is subject to the following: Abcam Restricted Use Statement
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.